Regentis Biomaterials Ltd.

RGNT

AMEXHealthcareMedical - Instruments & Supplies

在 GoAI 中打開

一般交易時段

US$2.0501

−US$0.0499 · -2.38%

8月24日上午10:43 ET

盤中時間採用ET。市場資料可能有所延遲。

公司概況

公司網站

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

產業: Medical - Instruments & Supplies
部門: Healthcare
總部: IL
執行長: Ehud Geller
上市以來: 2025年12月4日
僱員: 10

市場位置

日內區間

目前US$2.0501，

US$1.96US$2.18

52週區間

目前US$2.0501，

US$1.232US$15.50

開盤價: US$2.15
前收盤價: US$2.10
成交量: 1.58萬; 0× 平均值
平均成交量: 540.1萬; 日均成交量
市值: 1439.97萬 USD
貝塔: -0.69; 市場參考 1
50天平均值: US$2.8998; 低於平均水平-29.30%
200天平均值: US$3.8404; 低於平均水平-46.62%

RGNT 訊息

accessnewswire.com2026年7月20日

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting,…

閱讀原始碼

accessnewswire.com2026年7月15日

Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch

European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®, which is approved…

閱讀原始碼

accessnewswire.com2026年6月17日

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today…

閱讀原始碼

accessnewswire.com2026年6月8日

Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of Excellence designed…

閱讀原始碼